7:24 PM
 | 
Nov 17, 2014
 |  BC Extra  |  Company News

FDA approves Genzyme's Lemtrada

FDA approved Lemtrada alemtuzumab from the Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat adults with relapsing-remitting multiple sclerosis (RRMS) who have had an inadequate response to two or more prior treatments.

The agency approved the humanized mAb against CD52 with a REMS, and required that it...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >